Key Takeaway: Ovid has entered into a collaboration and option agreement with Gensaic to research and develop phage-derived particle products. This partnership aims to target certain rare disorders of the central nervous system using Gensaic's proprietary technology. The collaboration marks a significant step in Ovid's efforts to innovate in rare disease therapeutics.
Price reaction · baseline $3.515 (2023-09-22T16:09:00.000Z) · hit during market hours · 28 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration with Gensaic to develop innovative therapies.
Focus on central nervous system rare disorder targets.
Utilization of Gensaic's proprietary platform for research.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Full Press Release Details
In August 2022, the Ovid entered into a collaboration and option agreement (“Collaboration Agreement”) with Gensaic. The Collaboration Agreement involves the research and development of phage-derived particle (“PDP”) products on Gensaic’s proprietary platform for certain central nervous system rare disorder targets.
Read More »
Frequently Asked Questions
What is the focus of the Ovid and Gensaic collaboration?
The collaboration focuses on developing phage-derived particle products for central nervous system rare disorders.
When was the collaboration agreement with Gensaic signed?
The collaboration agreement was signed in August 2022.
What technology will be used in the collaboration?
The collaboration will utilize Gensaic's proprietary platform for research and development.
Biotech snapshot
Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk
Catalyst track record
+622%
best trade around OVID's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.